Paul Miller
2011-Aug-04 19:03 UTC
[R] Multiple endpoint (possibly group sequential) sample size calculation
Hello everyone, I need to do a sample size calculation. The study two arms and two endpoints. The two arms are two different cancer drugs and the two endpoints reflect efficacy (based on progression free survival) and toxicity. Until now, I have been trying to understand this in terms of a one-arm design, where the acceptable rate of efficacy might be 0.40, the unacceptable rate of efficacy might be 0.20, the acceptable rate of non-toxicity might be 0.85, and the unacceptable rate of non-toxicity might be 0.65. Then one would pick an alpha for the probability of accepting a poor response, an alpha for the probability of accepting a toxic drug, and a beta for the probability of rejecting a good drug. I'm not really sure how that sort of thinking translates into a two-arm design though. Ideally, I'd like the calculation to be based on a group sequential design with two stages, but that's certainly not necessary, and I'd be very happy to learn how to do things both with and without this extra element. Any help with this would be greatly appreciated. Thanks, Paul
Marc Schwartz
2011-Aug-04 20:57 UTC
[R] Multiple endpoint (possibly group sequential) sample size calculation
On Aug 4, 2011, at 2:03 PM, Paul Miller wrote:> > Hello everyone, > > I need to do a sample size calculation. The study two arms and two endpoints. The two arms are two different cancer drugs and the two endpoints reflect efficacy (based on progression free survival) and toxicity. > > Until now, I have been trying to understand this in terms of a one-arm design, where the acceptable rate of efficacy might be 0.40, the unacceptable rate of efficacy might be 0.20, the acceptable rate of non-toxicity might be 0.85, and the unacceptable rate of non-toxicity might be 0.65. Then one would pick an alpha for the probability of accepting a poor response, an alpha for the probability of accepting a toxic drug, and a beta for the probability of rejecting a good drug. > > I'm not really sure how that sort of thinking translates into a two-arm design though. > > Ideally, I'd like the calculation to be based on a group sequential design with two stages, but that's certainly not necessary, and I'd be very happy to learn how to do things both with and without this extra element. > > Any help with this would be greatly appreciated. > > Thanks, > > PaulHi Paul, I am not clear that there is a current R package that will handle both of these considerations, though will stand to be corrected if wrong. A Google search using "sample size calculation multiple endpoints" yields some possible theoretical papers that might be helpful, such as: http://www.ncbi.nlm.nih.gov/pubmed/20687162 http://www.ncbi.nlm.nih.gov/pubmed/17674404 I have used the gsDesign package on CRAN to assist with group sequential designs with a single primary endpoint. There was just a review in this month's The American Statistician which covered several software implementations, including gsDesign: http://pubs.amstat.org/doi/abs/10.1198/tast.2011.10213 There is also a CRAN Task View that might be helpful: http://cran.r-project.org/web/views/ClinicalTrials.html My various books on group sequential designs are at home, so am unable to check them at the moment, but pretty sure that at least Jennison and Turnbull (1999) have a chapter on multiple endpoints. HTH, Marc Schwartz
Maybe Matching Threads
- SPLUS Seqtrial vs. R Packages for sequential clinical trials designs
- Genentech Nonclinical Biostatistics Position in South San Francisco
- Nonclinical Biostatistics Opening at Genentech, South San Francisco
- gsDesign Pocock & OBF boundary
- Looking for help in calculating percentiles